10-Q: AN2 Therapeutics Reports Q1 2025 Financial Results; Epetraborole Phase 3 Trial Fails Primary Endpoint

AN2 Therapeutics announces Q1 2025 financial results and reports that the truncated Phase 3 portion of the EBO-301 study for epetraborole did not meet its primary endpoint, leading to the discontinuation of its development for treatment-refractory MAC lung disease.

Summary

• AN2 Therapeutics, a biopharmaceutical company, reported a net loss of $10.6 million for the three months ended March 31, 2025, compared to a net loss of $16.6 million for the same period in 2024.
• Research and development expenses decreased to $7.7 million from $14.7 million year-over-year, primarily due to the termination of the EBO-301 trial.
• The company's cash, cash equivalents, and investments totaled $78.5 million as of March 31, 2025.
• AN2 Therapeutics believes its current cash resources will be sufficient to fund operations for at least the next 12 months.
• The truncated Phase 3 portion of the EBO-301 study evaluating epetraborole did not meet its primary endpoint, leading to the discontinuation of its development for treatment-refractory MAC lung disease.
• The company is focusing on AN2-502998 for Chagas disease, epetraborole for melioidosis, and oncology programs.
• Phase 1 start-up activities have commenced for AN2-502998, with completion anticipated in the second half of 2025.
• Topline data from a 200-patient observational trial for melioidosis is expected in the second quarter of 2025, informing a planned Phase 2 proof of concept study in the second half of 2025.
• The company reduced its workforce by approximately 50% in August 2024 to extend operating capital.

Sentiment

Score: 4

Explanation: The document presents mixed signals. While the company has reduced its net loss and has sufficient cash to fund operations for the next 12 months, the failure of the Phase 3 trial and the workforce reduction are significant negative developments. The company's future success depends on the success of its remaining programs, which are still in early stages of development.

Positives

• The net loss decreased from $16.6 million in Q1 2024 to $10.6 million in Q1 2025.
• Research and development expenses decreased, reflecting a focus on core programs.
• The company believes its current cash, cash equivalents, and investments will fund operations for at least the next 12 months.
• Phase 1 start-up activities have commenced for AN2-502998, with completion anticipated in the second half of 2025.
• The company is advancing AN2-502998 for Chagas disease, epetraborole for melioidosis, and oncology programs.

Negatives

• The Phase 3 portion of the EBO-301 study for epetraborole in treatment-refractory MAC lung disease failed to meet its primary endpoint, leading to the program's discontinuation.
• The company has an accumulated deficit of $216.4 million as of March 31, 2025.
• The company reduced its workforce by approximately 50% in August 2024 to extend operating capital.
• The company has identified material weaknesses in its internal control over financial reporting.

Risks

• The company's future success depends on obtaining regulatory approval and successfully commercializing its product candidates.
• Clinical trials may fail to demonstrate the safety and/or efficacy of product candidates.
• The company relies on third parties to conduct preclinical studies and clinical trials.
• The company faces substantial competition from other pharmaceutical and biotechnology companies.
• The company operates with a small team and depends on its ability to retain key executives and attract qualified personnel.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company's rights to develop and commercialize its technology are subject to the terms and conditions of licenses granted by others.
• The company may be involved in lawsuits to protect or enforce its patents or other intellectual property.
• The company may be subject to claims by third parties asserting that it is infringing their intellectual property rights.
• The company may not be able to protect its intellectual property rights throughout the world.
• The company may not be able to obtain or maintain orphan drug designations for any product candidates.
• The company may attempt to seek accelerated approval in the United States for certain of its product candidates, but may not be able to use that pathway.
• The company may not be able to obtain or maintain orphan drug designations for any product candidates, and may be unable to take advantage of the benefits associated with orphan drug designation, including the potential for market exclusivity.
• The company may attempt to seek accelerated approval in the United States for certain of its product candidates. If it is not able to use that pathway, it may be required to conduct additional clinical trials beyond those that are contemplated, which would increase the expense of obtaining, and delay the receipt of, necessary regulatory approvals, if it receives them at all.
• The company is subject to privacy and data security laws, rules, regulations, policies, industry standards, and contractual obligations, and its failure to comply with them could harm its business.
• The company is subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair its ability to compete in domestic and international markets.
• The company is incurring significantly increased costs as a result of operating as a company whose common stock is publicly traded in the United States, and its management is devoting substantial time to new compliance initiatives.
• Significant disruptions of the company's or its vendors' information technology systems or cybersecurity incidents could result in significant financial, legal, regulatory, business, and reputational harm to the company.
• The company is an emerging growth company and as a result of the reduced disclosure and governance requirements applicable to emerging growth companies, its common stock may be less attractive to investors.
• If the company fails to adhere to the listing requirements of the Nasdaq Global Select Market its common stock could be delisted.
• Recent and potential future changes to U.S. and non-U.S. tax laws could materially adversely affect the company.
• Indemnity provisions in various agreements potentially expose the company to substantial liability for intellectual property infringement, data protection, and other losses.

Future Outlook

AN2 Therapeutics believes its current cash, cash equivalents, and investments will be sufficient to fund its planned operations under its current operating plan through at least twelve months following the date of this Form 10-Q. The company is focusing on AN2-502998 for Chagas disease, epetraborole for melioidosis, and oncology programs. Phase 1 start-up activities have commenced for AN2-502998, with completion anticipated in the second half of 2025. Topline data from a 200-patient observational trial for melioidosis is expected in the second quarter of 2025, informing a planned Phase 2 proof of concept study in the second half of 2025.

Management Comments

• Management believes that its cash, cash equivalents, and investments as of March 31, 2025 will be sufficient to fund its current operating plan through at least 12 months from the issuance date of these condensed financial statements.

Industry Context

The biopharmaceutical industry is highly competitive, with companies constantly striving to develop new and improved therapies. AN2 Therapeutics faces competition from major pharmaceutical companies, biotechnology companies, and academic institutions. The failure of the EBO-301 trial highlights the risks inherent in drug development, while the company's focus on new programs reflects a strategic shift to address unmet medical needs in infectious diseases and oncology.

Comparison to Industry Standards

• Given the failure of the Phase 3 trial for Epetraborole, it is difficult to compare AN2 Therapeutics to industry standards.
• However, similiar companies such as Spero Therapeutics and Atea Pharmaceuticals have also experienced Phase 3 failures, resulting in significant stock price declines and strategic shifts.
• AN2's focus on boron-based therapeutics is a niche area, making direct comparisons challenging.
• However, companies like RedHill Biopharma are also focused on niche infectious disease markets.
• AN2's cash runway of at least 12 months is comparable to other small-cap biopharmaceutical companies, but its burn rate will need to be carefully managed.

Corporate Governance

Legal Proceedings

• The Company was not subject to any material legal proceedings as of March 31, 2025 and December 31, 2024, and the Company is not currently a party to any legal proceeding that, if determined adversely to the Company, in managements opinion, is currently expected to individually or in the aggregate have a material adverse effect on the Companys business, financial condition or results of operations taken as a whole.

Related Party Transactions

• During the three months ended March 31, 2025 and 2024, the Company had no material related party transactions.

Stakeholder Impact

• Shareholders: The failure of the Phase 3 trial and workforce reduction may negatively impact shareholder value.
• Employees: The workforce reduction has impacted employees, and remaining employees may face increased workloads.
• Patients: The discontinuation of epetraborole development for MAC lung disease may limit treatment options for patients with this condition.
• Suppliers and CROs: The restructuring and program changes may affect relationships with suppliers and CROs.

Next Steps

• Complete Phase 1 study for AN2-502998 in the second half of 2025.
• Announce topline data from the melioidosis observational trial in the second quarter of 2025.
• Initiate start-up activities for a Phase 2 proof of concept study for melioidosis in the second half of 2025.
• Advance the first oncology compound(s) into development later this year with potential clinical proof of concept within the Company's current cash runway.

Key Dates

Keywords

AN2 Therapeutics, financial results, epetraborole, clinical trial, MAC lung disease, Chagas disease, melioidosis, oncology, research and development, regulatory approval, biopharmaceutical, net loss, workforce reduction, internal control, intellectual property